Merck to acquire Caraway Therapeutics in a deal worth up to $610m
AcquisitionADC
Preview
Source: PMLiVE
Merck & Co – known as MSD outside the US and Canada – has entered into a definitive agreement to acquire Caraway Therapeutics, with the deal worth up to $610m.
The acquisition gives Merck access to the preclinical biopharma’s pipeline of small-molecule therapeutics for genetically defined neurodegenerative and rare diseases.
Mutations that impair cellular clearance pathways are associated with multiple neurodegenerative and rare diseases, including neurodegenerative disorders characterised by cognitive dysfunction, according to Caraway.
The company focuses on discovering small molecules that activate cellular recycling processes to clear toxic materials and defective cellular components by modulating lysosomal function.
George Addona, senior vice president, discovery, preclinical development and translational medicine at Merck Research Laboratories, said: “Caraway’s multidisciplinary approach has yielded important progress in evaluating novel mechanisms of modulation of lysosomal function with potential for the treatment of progressive neurodegenerative diseases.
“We look forward to applying our expertise to build upon this work with the goal of developing much needed disease-modifying therapies for these conditions.”
Martin Williams, chief executive officer of Caraway Therapeutics, described the buyout as a "testament to the hard work and dedication of the Caraway team and [its] mission to develop therapeutics with the potential to alter the progression of devastating neurodegenerative diseases and help patients”.
He continued: “This acquisition leverages Merck’s industry-leading research and development capabilities to help further advance our discovery and preclinical programmes.”
The acquisition is just one of a series of deals that Merck has made this year. Last month, the company agreed to pay Daiichi Sankyo $5.5bn to jointly develop three of its antibody-drug conjugate candidates, with the transaction potentially worth up to $22bn.
Merck also announced in April that it would be acquiring Prometheus Biosciences for around $10.8bn, marking a significant boost to its immunology pipeline. The deal, which was completed in June, granted Merck access to Prometheus’ lead candidate being developed for ulcerative colitis, Crohn’s disease and other autoimmune conditions.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.